CRL · 10-Q · 2026Q3

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Filed 2026-11-04 · Other · View original filing on EDGAR

Everything CRL's SEC filings said, ranked

Ranked Events

• Income Tax Rate ChangesImportance 72 · Surprise 100
  The effective tax rate was (96.0)% in the third quarter of 2026, compared with 36.3% in the third quarter of 2025, as the company recorded a $163.8 million tax benefit instead of $31.6 million of tax expense. A $201…
• Liquidity and Debt PositionImportance 66 · Surprise 40
  Cash and cash equivalents totaled $200.4 million at September 26, 2026, down from $213.8 million at December 27, 2025; $195.8 million was held in non-U.S. entities. Total debt outstanding increased to $2.443 billion…
• Acquisition / Partnership / DivestitureImportance 65 · Surprise 60
  The company acquired an additional 79% interest in PathoQuest SAS on April 17, 2026, for $67.4 million, and acquired Cambodian NHP Supplier assets on January 14, 2026, for a preliminary purchase price of $507.3…
• Capital Return ProgramImportance 64 · Surprise 42
  The October 29, 2025 stock repurchase authorization permits up to $1.0 billion of buybacks. During the nine months ended September 26, 2026, the company repurchased 1.7 million shares for $300.0 million under the…
• Headcount and RestructuringImportance 62 · Surprise 42
  The Create the Future program combines workforce optimization, real-estate rationalization, procurement synergies, global business service expansion, process improvements, and AI-enabled automation. The company expects…
• Operating Margin DriversImportance 60 · Surprise 74
  Consolidated operating income increased 43.4% to $442.4 million for the nine months ended September 26, 2026, and operating margin rose 460 basis points to 14.8%. Manufacturing operating income rose $132.9 million to…
• Market Demand TrendsImportance 49 · Surprise 32
  Charles River reported an improving client spending environment, principally in Discovery and Safety Assessment (DSA), as biotech funding increased and global biopharmaceutical companies refocused investment on…
• FX / Currency ImpactImportance 49 · Surprise 6
  The company operates globally, with the Euro, Canadian Dollar, and British Pound among the principal functional currencies of its foreign subsidiaries; translation adjustments also reflected the Mauritian Rupee,…
• Operating Expense TrendsImportance 46 · Surprise 56
  Unallocated corporate costs increased $73.2 million, or 38.8%, to $261.8 million for the nine months ended September 26, 2026, and rose to 8.8% of revenue from 6.2%. The increase primarily reflected higher acquisition,…
• Strategic Cost ReductionImportance 40 · Surprise 42
  In the third quarter of fiscal 2026, the company announced Create the Future, a unified framework expanding its transformation and efficiency initiatives. The program includes process improvements, procurement…
• Interest Rate and Refinancing ExposureImportance 37 · Surprise 6
  At September 26, 2026, the company had $943.2 million outstanding under its revolving facility and $1.5 billion in Senior Notes, for total debt of $2.443 billion. The $2.0 billion multi-currency Credit Facility matures…
• Revenue Performance and MixImportance 31 · Surprise 32
  Revenue for the nine months ended September 26, 2026 decreased 1.3% to $2,982.6 million from $3,021.2 million, while third-quarter revenue fell 2.2% to $982.7 million. Nine-month service revenue declined 2.5% to…
• Operating Cash Flow TrendsImportance 29 · Surprise 22
  Net cash provided by operating activities was $474.9 million for the nine months ended September 26, 2026, down from $590.1 million in the same 2025 period. The $115.2 million decline primarily reflected higher…
• Manufacturing Market DemandImportance 26 · Surprise 24
  Manufacturing revenue was affected by the CDMO business sale, while demand-driven growth occurred in the retained businesses. Microbial Solutions revenue increased $24.7 million over the first nine months, driven…
• Capital ExpendituresImportance 24 · Surprise 14
  Capital expenditures were $133.8 million for the nine months ended September 26, 2026, compared with $130.2 million in the same 2025 period. Investing activities used $369.5 million, including $467.3 million for…
• RMS Geographic DemandImportance 20 · Surprise 24
  Research Models and Services (RMS) revenue trends varied by product and geography over the first nine months of 2026. Small research model product revenue in China increased $11.3 million, while small research model…

Revenue by Product (in thousands)

Revenue by Geography (in thousands)